Roche Climbs As Once-Daily Weight Loss Pill Shows Promise

Topline Roche said it had promising results from an ongoing trial for its obesity pill and would progress to ... [+] midstage trials. Roche said patients taking its experimental once-daily oral drug, CT-996, for four weeks lost an average of 6.1% of their starting bodyweight compared to patients who received a placebo. The CT-996 drug belongs to the same family of GLP-1 hormone mimicking drugs as blockbuster injections like Ozempic, Wegovy, Mounjaro and Zepbound and Roche said the study indicates it is safe ...